31 results about "Galactoside" patented technology

The application provides a galactoside agglutinin 10 (Gal10) crystal and a preparation method and prepared antibody IgY and a pharmaceutical preparation thereof, and belongs to the technical field of medicines. The application uses the galactoside agglutinin 10 crystal as an antigen to prepare an egg yolk neutralizing antibody IgY capable of dissolving the Gal10 crystal, has the effects of improving rhinitis or asthma of a patient, preventing and treating rhinitis and asthma, and is safe, has no side effects, has a long-lasting curative effect, and has no drug resistance, thereby providing a safe, simple, hygienic, effective, economic and personalized treatment mode for prevention and treatment of rhinitis and asthma, and having a high market value.

The invention relates to a preparation method and application of erythritol galactoside. The method specifically comprises the following steps: constructing a reaction system which takes o-nitrobenzene-beta-D-galactopyranoside as a glycosyl donor, erythritol as a receptor and recombinant beta-galactosidase Bga7 as a catalytic enzyme, so as to prepare the erythritol-beta-galactoside. Wherein the amino acid sequence of the beta-galactosidase Bga7 is as shown in SEQ ID No.2, and the nucleotide sequence of the beta-galactosidase Bga7 is as shown in SEQ ID No.1. The invention also provides an application of the erythritol-beta-galactoside in preparation of daily chemical products or medical preparations for resisting streptococcus mutans infection. The invention provides a novel beta-galactosidase Bga7 gene of a glycosidase family 2, and a novel tool enzyme is provided for synthesis of galactoside products. The erythritol-beta-galactoside prepared by the invention has good effects of preventing streptococcus mutans infection and caries, and can be used for preparing daily chemical products or medical preparations for preventing streptococcus mutans infection.

The invention discloses a method for improving yield of anthocyanin extracted by an enzymic method, according to the method, phospholipase is added and used to act on a cell membrane structure, so that the extraction rate of the anthocyanin and the extraction rate of galactoside in the anthocyanin are obviously improved, and the extraction effect of the anthocyanin is greatly improved through a three-stage enzymolysis system. The total enzymolysis extraction time is within 4 h, and compared with 6-7 h of a traditional enzymatic extraction process, the production period is greatly shortened.

The present invention relates to a method for producing α-sialyl-β-D-galactoside saccharides, particularly α-sialyl-(2→3)-β-D-galactoside saccharides and α-sialyl-(2→6)-β-D-galactoside saccharides, from a β-D-galactoside saccharide, a sialic acid donor, and an enzyme with β-galactoside α-sialyltransferase activity. The enzymes with β-galactoside α-sialyltransferase activity used herein do not exhibit catalytic activity towards the hydrolysis of cytidine 5'-monophospho-N-acetyl-neuraminic acid to cytidine and N-acetyl-neuraminic acid. The method can be performed in vitro and in vivo using a genetically engineered cell comprising a nucleic acid encoding said enzyme. Further, said process may be adapted to produce the sialic acid donor CMP-Neu5Ac from low-cost substrates N-acetyl-D-glucosamine (GlcNAc), pyruvate, a cytidine phosphate (CMP, CDP or CTP) and polyphosphate in a single reaction mixture with a set of optionally immobilized or optionally co-immobilized enzymes comprising N-acylglucoamine 2-epimerase (AGE), an N-acetylneuraminate lyase (NAL), an N-acylneuraminate cytidylyltransferase (CSS), optional a uridine kinase (UDK), a uridine monophosphate kinase and a polyphosphate kinase 3 (PPK3).

The invention belongs to the technical field of biological medicine, and particularly relates to a diglycerol linolenate galactoside compound in pepper as well as a preparation method and application of the diglycerol linolenate galactoside compound. The preparation method comprises the following steps: (1) taking red peppers to prepare pretreated red peppers; (2) adding the pretreated red peppers into an ethanol solution, performing ultrasonic extraction, and collecting first filtrate and first filter residues; (3) adding an ethanol solution into the first filter residue, carrying out ultrasonic extraction, combining the first filtrate and the second filtrate, and concentrating to obtain a crude extract; (4) separating the crude extract by adopting high-speed counter-current chromatography to obtain a primary purified product; and (5) further separating and purifying the primary purified product by adopting high performance liquid chromatography, and identifying to obtain the diglycerol linolenate galactoside compound. The purity of the diglycerol linolenate galactoside compound obtained by the preparation method is as high as 99.3%, and the diglycerol linolenate galactoside compound has a remarkable scavenging effect on DPPH free radicals, shows good antioxidant activity and has a wide application prospect.

The application discloses application of ZmGOLS2 genes and ZmRAFS genes in improving pollen vitality of corn under heat shock and drought conditions, and belongs to the technical field of genetic engineering. The application improves the pollen vitality of corn, promotes the germination of pollen under heat shock and drought stress conditions, and reduces the empty stalk rate of corn under drought stress conditions by simultaneously improving the expression levels of a corn myo-inositol galactoside synthetase coding gene and a corn raffinose synthetase coding gene.

The application provides a genetically engineered bacterium for producing lactose-N-neotetraose, a construction method and application thereof. The genetically engineered bacterium satisfies the following conditions: (1) exogenous expression of MFS transporter protein, beta-1, 3-N-acetylglucosamine transferase and beta-1, 4-galactosyltransferase; (2) overexpression of galactoside permease and UDP-galactose-4-epimerase; and (3) no expression or weakened expression of setA transporter protein. The applicant of the application finds through research that exogenous introduction of MFS transporter protein, beta-1, 3-N-acetylglucosamine transferase and beta-1, 4-galactosyltransferase in the genetically engineered bacterium, enhancement of the expression amount of galactoside permease and UDP-galactose-4-epimerase in the genome, and reduction of the expression amount of setA transporter protein can effectively reduce the residual amount of LNT II in the LNnT synthesis pathway and improve the fermentation yield of LNnT.

The application discloses a beta-galactoside enzyme mutant and application thereof. The application takes wild-type beta-galactoside enzyme Bgal1-3 as a parent to provide a mutant with improved thermal stability, enzyme activity and / or oligogalactose production capacity compared with the parent. Meanwhile, the application takes the mutant M9 of Bgal1-3 as a parent to provide a mutant with improved hydrolysis activity compared with the parent. The beta-galactoside enzyme mutant can be used for converting lactose to produce low / zero-lactose or oligogalactose-rich dairy products, and is beneficial to the development of low / zero-lactose or oligogalactose-rich dairy product related industry.

This invention provides the application of glucose-responsive nanohydrogels in the preparation of drugs for treating skin injuries. The method includes the following steps: mixing hyaluronic acid with a phenylboronic acid compound, adding 3-aminophenylboronic acid, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride and N-hydroxysuccinimide, and performing a grafting reaction to obtain boric acid-modified hyaluronic acid; adding myricetin-3-O-galactoside, phospholipids, and cholesterol to an organic solvent, followed by thin-film hydration and ultrasonic treatment to obtain nanoliposomes; mixing the boric acid-modified hyaluronic acid with a polyvinyl alcohol solution, then adding the nanoliposome solution, and finally mixing to obtain the resulting nanohydrogel. The glucose-responsive nanohydrogel of this invention achieves adaptive drug release in the high glucose environment of diabetic wounds and regulates local metabolic homeostasis of the wound, especially the lysine degradation pathway in amino acid metabolism.

The application discloses a kind of similar bundle-like arabino-galactoside protein coding gene GhFLA2 In the application of regulating cotton seed vigor, the application obtains several overexpression materials, RNA interference materials and gene knockout materials by transgenic technology GhFLA2 It is found that overexpression GhFLA2 Can promote radicle elongation during seed germination and cotyledon unfolding after germination, GhFLA2 After the expression amount of the application is reduced or knocked out, radicle elongation and cotyledon development are inhibited.The application provides a new gene target for cotton seed vigor improvement.

The application discloses a composition for alleviating the irritation of hair dyeing and a preparation method and application thereof, and the composition contains, in percentage by mass, 0.1-50% of a hook sand plant extract, 0.01-10% of a gelidium esculentum extract and 0.1-60% of a sargassum muticum extract. The hook sand plant extract, the gelidium esculentum extract and the sargassum muticum extract are compounded, and it is found that the obtained composition is rich in various proteins, sugars, vitamins, organic acids, mineral salts and trace elements, and the unique galactoside sulfate in the composition forms a firm protective film through ion-ion interaction between the amino groups of the skin and hair keratin and the amino groups of the galactoside sulfate, thereby alleviating the irritation of external chemicals, and the hydrogen bond between the hydroxyl groups and water has a good moisturizing effect and enhances the barrier function. The composition has the effect of alleviating the irritation of a hair dye to the scalp skin and hair during the hair dyeing process, and is helpful to dyeing, so that the hair is more colored.

The invention discloses a method for producing D-tagatose with high efficiency and low cost. According to the invention, a double-enzyme cascade engineering strain B.subtilis WB800N-pHT01-araA-lacZ, which can be used for simultaneously expressing a beta-galactosidase gene lacZ and an L-arabinose isomerase gene araA, is constructed, and the double-enzyme cascade engineering strain B.subtilis WB800N-pHT01-araA-lacZ is constructed; culturing the engineering strain, centrifugally collecting thalli, resuspending the collected thalli by using a substrate solution containing whey powder (lactose), and reacting at constant temperature; and finally, centrifuging the reaction liquid after the reaction is finished, taking supernate, filtering the supernate through a 0.22 m water system small filter, and determining the D-tagatose in the supernate by high performance liquid chromatography, the yield of the D-tagatose being up to 77.5 g / L. The method provided by the invention can realize efficient reutilization of the milk product byproduct whey powder, and has the advantages of simple operation method, mild reaction conditions, high efficiency, low cost and the like.

This invention provides the application of a directed mutant glycosyltransferase in the synthesis of galactoside anthocyanins, belonging to the field of enzyme engineering technology. This invention provides a glycosyltransferase mutant, wherein the mutant includes mutations at at least one of the following sites in the amino acid sequence of the glycosyltransferase Vc3GT: position 82, position 139, and position 322. The embodiments of this invention verify the synthesis and catalytic efficiency of the mutants, showing that each mutant can be ligated into an expression vector and, through genetic transformation, a recombinant expression host capable of producing the corresponding mutant protein can be obtained. Furthermore, the recombinant protein obtained after induced expression possesses in vitro enzymatic catalytic activity, and can use malvidin and UDP-galactoside as substrates to catalyze the synthesis of malvidin-3-O-galactoside. The catalytic method is simple, the process cost is low, and it is suitable for large-scale industrial production.

The invention discloses a positive ion metabolism marker for thyroid-associated ophthalmopathy, a product and application of the positive ion metabolism marker. The positive ion marker is prepared from any one or more of L-arginine-L-valeryl-L-lysine, cholesterol beta-epoxide, phosphatidylcholine (18: 4 / 20: 5), sphingosine galactoside and oestrone. The invention provides a kit which comprises a detection reagent for detecting the positive ion marker. A computer program product associated with thyroid-related ocular diseases is provided. The product provided by the invention has good feasibility and accuracy, can effectively evaluate the risk of thyroid-related eye diseases, and provides a new tool for clinical diagnosis.

This invention relates to a comprehensive evaluation method for the quality of Pinellia ternata and a method for constructing a fingerprint spectrum of Pinellia ternata. The method includes: processing Pinellia ternata to obtain a test solution; preparing a reference solution containing guanosine, phenylalanine, VGTNY, tryptophan, LFSG, apigenin-6-C-arabinose-8-C-galactoside, PWVPG, NIPF, and VIYGPSVF; injecting the test solution and the reference solution separately into a liquid chromatography-mass spectrometry (LC-MS) instrument, and obtaining the fingerprint spectrum of the Pinellia ternata using LC-MS. A method for determining the content of toxic components calcium oxalate needle crystals and lectin protein is also established. The comprehensive evaluation method for the quality of Pinellia ternata provided by this invention comprehensively improves the evaluation standards for Pinellia ternata, ensuring the effectiveness and safety of Pinellia ternata in clinical use.

The invention discloses an arbutin analogue, a preparation method thereof and application of the arbutin analogue in preparation of a medicine for treating chronic colitis, and belongs to the technical field of medicines. The arbutin analogue is structurally characterized in that a galactosyl group is connected with a polysubstituted benzene ring through a flexible connecting chain-(CH) n-O-to form a novel structure which is remarkably different from a known compound arbutin. The arbutin analogue is prepared through chemical synthesis, and a pharmaceutical composition containing the arbutin analogue is provided. Pharmacological experiments prove that the representative compounds hydroquinone monogalactoside and 3, 4-dihydroxyphenol galactoside show disease treatment activity obviously superior to that of arbutin in a DSS-induced mouse chronic colitis model, the disease activity index can be effectively improved, and colon tissue damage can be relieved. Therefore, the compound provided by the invention can be used for preparing medicines for preventing and / or treating chronic colitis. Formula (1)

FIELD: neurology; laboratory diagnostics.SUBSTANCE: used for the differential diagnosis of Parkinson's disease not associated with mutations in the GBA1 gene, and multiple system atrophy. The patient's peripheral venous blood is collected, from which mononuclear cells are isolated by gradient centrifugation, followed by their differentiation into a primary culture of macrophages in the presence of the macrophage colony-stimulating growth factor M-CSF to ensure proliferation and differentiation of monocytes into mature macrophages. The obtained blood macrophage cells are applied to 903 filter cards at a concentration of 2×106 cells / ml. Whatman 903 Sample Collection Cards can be used as 903 filter cards. The activity of lysosomal enzymes is determined: glucocerebrosidase GCase, alpha-galactosidase GLA, acid sphingomyelinase ASMase, galactosylceramidase GALC by high-performance liquid chromatography in combination with tandem mass spectrometry. The value of the canonical linear discriminant function CLDF is calculated using the stated formula. If the value of CLDF is ≥ 43.44, the patient is diagnosed with multiple system atrophy. If the value of CLDF is < 43.44, Parkinson's disease is diagnosed in patients who do not have a mutation in the GBA1 gene.EFFECT: method enables reliable and accurate differential diagnosis of Parkinson's disease and multiple system atrophy by assessing the activity of lysosomal enzymes.2 cl, 2 dwg, 2 ex

This invention belongs to the field of biotechnology, specifically relating to the GmSGT2 gene and its mutants related to plant height and branching development, and their applications. Specifically, this invention obtains a soybean mutant with fewer branches and reduced plant height through EMS mutagenesis, and locates the target gene as the GmSGT2 gene of soybean variety 'He Dou 12' using map-based cloning technology. Searching reveals that this gene encodes soybean saponin B glucuronide galactosyltransferase, which can galactosylate soybean saponin B monoglucuronide, thus affecting soybean plant height and reducing branching. Therefore, the gmsgt2 mutant can be used to breed dwarf, high-yielding soybean varieties, which is of profound significance in breeding ideal soybean plant architecture and research on important agronomic traits. It has broad application prospects and high research value for understanding the regulation mechanism of soybean plant height and branching, improving the soybean breeding process, and can provide excellent germplasm resources for regulating soybean dense planting and high-yield breeding.

Disclosed in the present invention are a compound represented by formula (I) and a pharmaceutically acceptable salt thereof. Specifically, disclosed in the present invention are a tetrazolyl-substituted pyran galactoside derivative as a Gal-3 inhibitor and a preparation method therefor and a use thereof.

The present invention relates to mutant galactoside permeases, in particular microbial host cells and fermentation processes employing mutant galactoside permeases that display reduced or abolished proton-coupled transport activity while retaining substrate translocation. These permease variants, when expressed at levels exceeding endogenous wild-type expression, enable cultivation and production processes, in particular in the presence of elevated lactose concentrations without the growth limitations typically associated with lactose-induced energetic collapse. The invention further relates to genetic constructs, metabolic pathways, and process strategies suitable for the production of lactose-based products, such as human milk oligosaccharides.

To provide a cosmetic composition using a natural pigment and excellent in luminescence.SOLUTION: The cosmetic composition contains a natural pigment and an alkyl galactoside having a 4-22C alkyl group. The method for producing the cosmetic composition includes a step of mixing a natural pigment with a crystal of an alkyl galactoside having a 4-22C alkyl group.SELECTED DRAWING: Figure 1

An ultrasensitive and long-lasting luminescence cascade can be used for point-of-care detection. A reaction chamber can receive and incubate a volume of a sample and a volume of magnetic tag solution before the combination is washed. Then, a working solution including d-luciferin-6-O-β-d-galactopyranoside (LUGAL), firefly luciferase (Fluc), and a luminescence buffer comprising ATP can be added to the reaction chamber. When the reaction chamber also includes tagged target components including beta galactosidase (GAL) then the GAL supplies luciferin intermediates that catalyze the cleavage of a protecting group from the LUGAL, generating luciferin, and the Fluc catalyzes the oxidation of D-luciferin in a presence of the ATP and O2, yielding oxyluciferin and luminescence. Repeated catalytic cycles increase a measurable signal of the luminescence. An optical sensor can capture an image of the luminescence and the presence of tagged target components can be determined based on an amount of luminescence in the image.

The invention relates to the technical field of food processing, in particular to a preparation method of low-lactose fermented cream cheese suitable for people with lactose intolerance. Through the key steps of stabilizer pretreatment, sectional beta-galactoside enzymolysis, compound leavening agent acid-controlled fermentation, low-temperature centrifugation, homogenizing redissolution and the like, the lactose residue is further reduced, and meanwhile, the excellent texture and flavor are kept. The method does not need ultrafiltration equipment, the enzyme can be recycled, the method is suitable for industrial production, the contradiction between incomplete lactose removal and texture deterioration in the prior art is solved, and the method has remarkable economic benefits and social values.

The application belongs to the technical field of biology, and discloses application of gallic acid derivatives in preparation of products for treating or preventing liver diseases, wherein the gallic acid derivatives are one or more combinations of 2-Phenylethyl 1-O-beta-D-(6'-O-galloyl)-glucopyranoside, 2,3-digalloyl-D-glucopyranose, Kaempferol 3-O-glucoside-2"-gallate and Quercetin 3-O-(6'-O-Galloyl)-beta-galactoside; the four gallic acid derivatives can better reduce AST and ALT activities in alcohol-induced HepG2 cells relative to a model group, and 2,3-digalloyl-D-glucopyranose and Quercetin 3-O-(6'-O-Galloyl)-beta-galactoside have better effects than gallic acid and positive drug Silybin (Silybin).

The present application relates to compounds of formula (I) and salts and solvates thereof, wherein A1, A2, A3 and R1, R2, R 3a , R 3b , R4 and R5 are as defined in the description, and their use for the treatment and / or prevention of disorders and conditions associated with an altered activity of β-galactosidase, in particular galactoside β-1 or GLB1, including GM1 gangliosidosis and Morquio syndrome B.

The invention discloses an application of a galactosidase gene GbGAL1 in improvement of yield traits of cotton fibers. The galactosidase gene GbGAL1 has two haplotypes, the genomic sequence of the haplotype 1 is SEQ ID NO.1, and the CDS sequence of the haplotype 1 is SEQ ID NO.2; the genomic sequence of the haplotype 2 is SEQ ID NO.4, and the CDS sequence of the haplotype 2 is SEQ ID NO.5. SNAP primers for identifying the two haplotypes are further developed, and the sequences of the SNAP primers are respectively SEQ ID NO. 9 and SEQ ID NO. 10. When the haplotype 2 gene sequence or the protein coded by the haplotype 2 gene exists in a cotton plant, the allele or the protein of the allele can promote the cotton boll weight or lint percentage increase, which shows that the haplotype 2 gene has important effect and application prospect in improving the cotton yield character and cultivating a new high-yield cotton variety.

The application discloses a kind of β-galactoside enzyme activated near-infrared fluorescent probes, the structural formula of the fluorescent probe Gal-QCS is as follows: the response site of β-Gal is introduced on the good nature semi-florin fluorophore of the fluorescent probe, the fluorescence of probe itself is quenched due to intramolecular charge transfer effect, after reacting with β-Gal again, glycosidic bond is hydrolyzed, so that its fluorescence recovers. By the change of absorption wavelength and fluorescence wavelength before and after response, the quantitative detection of β-Gal can be realized;The emission wavelength of the fluorescent probe is longer, can quickly, specifically identify β-Gal, has higher signal-to-background ratio, reduces the error caused by background fluorescence.

The present application relates to the technical field of biological medicine, and discloses a beta-galactoside enzyme activated AIE type photosensitizer and a preparation method and application thereof. The present application provides an AIE photosensitizer, which is a compound (1) with a structural formula as shown in formula (1). When the galactose group exists, the power supply group is shielded, the ICT effect is weakened, and the PDT performance is in a closed state. When the galactose group is hydrolyzed by beta-galactosidase, the overall water solubility of the compound (1) from which the galactose group is hydrolyzed becomes poor, and the compound (1) is aggregated. Meanwhile, the power supply group hydroxyl is opened, the ICT effect is enhanced, and the PDT performance is in an open state. The glycosidase activity in ovarian cancer cells is abnormally increased, and the glycosidase in ovarian cancer cells triggers the AIE photosensitizer to be activated in the tumor microenvironment with high glycosidase activity, so that precise positioning is achieved. This selective activation mode significantly reduces the misactivation of the photosensitizer in normal tissues and reduces the damage to healthy tissues.

The invention discloses a salt activated beta-galactosidase mutant E154V and application thereof. The amino acid sequence of the mutant is shown as SEQ ID NO. 1. In a system without adding salt, the hydrolytic activity of E154V to a substrate p-nitrophenyl-beta-D-galactopyranoside (pNPG) is lower, the activity of E154V in a system with salt is remarkably improved, and in a 500 mM potassium acetate solution, the hydrolytic activity of the mutant to the pNPG is improved by 11.41 times and is improved by 124.26% compared with that of a recombinant wild enzyme without adding salt; the hydrolytic activity to galactooligosaccharide is improved by 22.13 times, and is improved by 58.72% compared with that of a recombinant wild enzyme without salt. The mutant is suitable for a technical application scene in which the enzymatic reaction rate needs to be adjusted, the reaction efficiency and controllability can be effectively improved, and a better solution is provided for enzyme catalysis application in the fields of agriculture, food processing, biotechnology and the like.

The application discloses a method based on solid-phase glycoprotein T antigen glycopeptide enrichment and enzyme cutting analysis, which comprises the following steps: extracting protein from a sample; obtaining polypeptide through proteolysis; oxidizing galactose and N-acetyl galactose; fixing with hydrazide resin and cutting with PNGase F enzyme; treating with galactoside enzyme and performing mass spectrometry analysis. The method obtains three structures, T antigen glycopeptide of core 1, core 2 glycopeptide and core 8 glycopeptide. The T antigen glycopeptide and the core 2 glycopeptide are distinguished through mass spectrometry analysis, and the T antigen glycopeptide and the core 8 are distinguished through different glycosidases. The method can enrich and distinguish glycopeptides containing T antigens, core 2 and core 8, and has important significance for finding specific markers with T antigen modification in tumor tissues and body fluids, research on early diagnosis and prognosis markers of diseases and the like.